Cryptolepine在体外和体内均抑制血小板聚集，并在体外刺激纤维蛋白溶解。

Cryptolepine inhibits platelet aggregation in vitro and in vivo and stimulates fibrinolysis ex vivo.

Oyekan A O, Botting J H, Noamesi B K

Department of Pharmacology, King's College, University of London.

Gen Pharmacol. 1988;19(2):233-7. doi: 10.1016/0306-3623(88)90067-5.

Abstract

Cryptolepine--the methylquindolanol alkaloid of Cryptolepsis sanguinolenta was evaluated for its antiplatelet and fibrinolytic effects. 2. It exhibited antiplatelet effects in vitro in human, rabbit and rat PRP with EC50 values ranging between 8.1 x 10(-8) M and 1.7 x 10(-7) M for ADP, AA and thrombin. 3. In the rat, it inhibited ADP-aggregation in vivo with delayed onset and prolonged action. 4. In vitro, cryptolepine disaggregated (dose-dependently) platelets aggregated by ADP, AA and thrombin. 5. In addition, it exhibited an indirect fibrinolytic action in the rat possibly by causing the release of plasminogen activators from the vascular endothelium.

摘要

对血根叶白叶藤的甲基喹多醇生物碱——隐丹参酮的抗血小板和纤溶作用进行了评估。2. 它在体外对人、兔和大鼠的富血小板血浆表现出抗血小板作用，对ADP、花生四烯酸（AA）和凝血酶的EC50值在8.1×10⁻⁸ M至1.7×10⁻⁷ M之间。3. 在大鼠体内，它抑制ADP诱导的聚集，起效延迟且作用持久。4. 在体外，隐丹参酮能（剂量依赖性地）使由ADP、AA和凝血酶诱导聚集的血小板解聚。5. 此外，它在大鼠体内可能通过促使血管内皮释放纤溶酶原激活剂而表现出间接纤溶作用。